Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression

Tags

  • Category: Articles

AUTHORS

Patricia P. Yee, Yiju Wei, Soo-Yeon Kim, Tong Lu, Stephen Y. Chih, Cynthia Lawson, Miaolu Tang, Zhijun Liu, Benjamin Anderson, Krishnamoorthy Thamburaj, Megan M. Young, Dawit G. Aregawi, Michael J. Glantz, Brad E. Zacharia, Charles S. Specht, Hong-Gang Wang & Wei Li.

SUMMARY

Tumor necrosis commonly exists and predicts poor prognoses in many cancers. Although it is thought to result from chronic ischemia, the underlying nature and mechanisms driving the involved cell death remain obscure. Here, we show that necrosis in glioblastoma (GBM) involves neutrophil-triggered ferroptosis. In a hyperactivated transcriptional coactivator with PDZ-binding motif-driven GBM mouse model, neutrophils coincide with necrosis temporally and spatially. Neutrophil depletion dampens necrosis. Neutrophils isolated from mouse brain tumors kill cocultured tumor cells. Mechanistically, neutrophils induce iron-dependent accumulation of lipid peroxides within tumor cells by transferring myeloperoxidase-containing granules into tumor cells. Inhibition or depletion of myeloperoxidase suppresses neutrophil-induced tumor cell cytotoxicity. Intratumoral glutathione peroxidase 4 overexpression or acyl-CoA synthetase long chain family member 4 depletion diminishes necrosis and aggressiveness of tumors. Furthermore, analyses of human GBMs support that neutrophils and ferroptosis are associated with necrosis and predict poor survival. Thus, our study identifies ferroptosis as the underlying nature of necrosis in GBMs and reveals a pro-tumorigenic role of ferroptosis. Together, we propose that certain tumor damage(s) occurring during early tumor progression (i.e. ischemia) recruits neutrophils to the site of tissue damage and thereby results in a positive feedback loop, amplifying GBM necrosis development to its fullest extent.

REFERENCES

Yee, P.P., Wei, Y., Kim, SY. et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun 11, 5424 (2020). https://doi.org/10.1038/s41467-020-19193-y

PRODUCT HIGHLIGHTS

The following Bio X Cell in vivo monoclonal antibodies were featured in the publication:

Back to News

Meet Our Leaders

Learn more about the team behind the gold standard in vivo antibodies.

Discover Bio X Cell

Learn more about our proven expertise and comprehensive antibody solutions.

See Our Impact

Discover the Bio X Cell Fund’s mission to improve the health of our community

Explore Our Latest

See our latest articles and whitepapers for scientific insights and ideas

Don’t see what you need?

Consult With Bio X Cell to Enable Your Next Breakthrough Discovery

Whether you need antibody customization or high-volume production, Bio X Cell is committed to advancing your therapeutic innovations.

Contact Us